The next transformative phase of weight-loss medication is upon us, with the US Food and Drug Administration (FDA) approving Novo Nordisk's highly anticipated oral GLP-1 drug – with a starting dose ...

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

The U.S. FDA approved a pill version of the weight-loss injection 'Wegovy', which is likely to be launched in January 2026.

This new pill contains the same active ingredient as injectable Wegovy and Ozempic, semaglutide. It is the first GLP-1 pill ...

The FDA has approved a pill form of the popular GLP-1 weight-loss medication Wegovy. Novo Nordisk says it is as effective as ...

The FDA has approved the first-ever Wegovy pill for weight loss, with the oral GLP-1 offering a 16.6% average weight ...

The Food and Drug Administration has approved the first GLP-1 pill for weight loss and maintenance. Drugmaker Novo Nordisk ...

In the studies the company submitted to the FDA, people who took the daily Wegovy pill lost about the same amount of ...

A daily weight-loss pill will soon be available in the US, after the regulator gave approval to Danish drug company Novo ...

The approval marks the first time an oral drug has been authorised specifically to treat obesity, offering an alternative to ...

Wegovy's new pill has been approved in the US, offering a needle-free option with a lower starting price than injections.

LONDON, Dec 23 () - Novo Nordisk's newly approved weight-loss pill version of Wegovy will be a test case for the fast-growing ...